Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (1672)	9/17/2000 12:36:47 AM
From: PuddleGlum	Respond to of 52153

Tom- I noticed GERN mentioned in that press release. But this, from a recent press release is why I like to include ARIA in the stem cell group: ARIAD intends to establish its RAGE technology - along with its proprietary gene regulation technologies, ARGENT and RAPID - as the technologies of choice for biotechnology and pharmaceutical companies to use in their genomics, proteomics, and drug discovery programs and in therapeutic protein manufacturing. Copies of the new ARIAD patent (U.S. Patent No. 6,117,689), as well as a prior patent relating to the RAGE technology (U.S. Patent No. 6,015,709) are available on the World Wide Web at uspto.gov. ARIAD Pharmaceuticals, Inc. (www.ariad.com) is a leader in the discovery and development of gene therapy, cell therapy, stem cell therapy and protein therapy products featuring dose-dependent regulation by small-molecule drugs, as well as small-molecule inhibitors of signal transduction. For full text, see biz.yahoo.com